ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

ABCL AbCellera Biologics Inc

2.20
0.00 (0.00%)
Pre Market
Last Updated: 09:48:47
Delayed by 15 minutes
Share Name Share Symbol Market Type
AbCellera Biologics Inc NASDAQ:ABCL NASDAQ Common Stock
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 2.20 2.25 2.26 721 09:48:47

AbCellera to Present at Upcoming Investor Conferences in November 2024

22/10/2024 9:05pm

Business Wire


AbCellera Biologics (NASDAQ:ABCL)
Historical Stock Chart


From Sep 2024 to Mar 2025

Click Here for more AbCellera Biologics Charts.

AbCellera (Nasdaq: ABCL) today announced that executives from the Company will be presenting at the following investor conferences:

  • Stifel Healthcare Conference on Monday, November 18, 2024, at 8:30 a.m. Pacific Time (11:30 a.m. Eastern Time)
  • Jefferies London Healthcare Conference on Tuesday, November 19, 2024, at 10:00 a.m. Pacific Time (5:00 p.m. Greenwich Mean Time)

Live audio webcasts of each presentation may be accessed through links that will be posted on AbCellera's Investor Relations website. Replays of each webcast will be available through the same links following the presentations.

About AbCellera Biologics Inc.

AbCellera (Nasdaq: ABCL) discovers and develops antibody medicines for indications across therapeutic areas, including cancer, metabolic and endocrine conditions, and autoimmune disorders. AbCellera’s engine integrates technology, data science, infrastructure, and interdisciplinary teams to solve the most challenging antibody discovery problems. AbCellera is focused on advancing an internal pipeline of first-in-class and best-in-class programs and collaborating on innovative drug development programs with partners. For more information, please visit www.abcellera.com.

Inquiries

Media: Kathleen Reid; media@abcellera.com, +1(236)521-6774 Business Development: Murray McCutcheon, Ph.D.; partnering@abcellera.com, +1(604)559-9005 Investor Relations: Peter Ahn; ir@abcellera.com, +1(778)729-9116

1 Year AbCellera Biologics Chart

1 Year AbCellera Biologics Chart

1 Month AbCellera Biologics Chart

1 Month AbCellera Biologics Chart

Your Recent History

Delayed Upgrade Clock